Kovacs, Janos, Pákáski, Magdolna, Juhasz, Anna, Feher, Agnes, Drótos, Gergely, Fazekas, Csilla Orsike, Horvath, Tamas Laszlo, Janka, Zoltan, Kálmán, János

Throughout the natural progression of Alzheimer’s disease (AD), the body mass index (BMI) decreases. This is believed to be brought on by the disturbance in the central lipid metabolism, but the exact mechanism is yet unknown. Adipokines (adiponectin, leptin), hormones produced by the adipose tissue, change glucose and lipid metabolism, and have an anorectic effect […]

Pietrzak, R. H., Maruff, P., Snyder, P. J.

Objectives: Change in cognitive function in response to a pharmacologic challenge can be observed with greater sensitivity by employing cognitive tests with optimal psychometric properties and a statistical approach that more accurately accounts for individual variability in performance. To demonstrate this approach we examined the cognitive effects of a single acute dose administration of an […]

Daiello, Lori A., Ott, Brian R., Festa, Elena K., Friedman, Michael, Miller, Lindsay A., Heindel, William C.

Objective: We conducted a combined observational cohort and case-control study in patients with Alzheimer disease (AD) to assess the effects of acetylcholinesterase inhibitor (ChEI) treatment on cognitive functions important for driving.; Methods: Performance of 24 outpatients with newly diagnosed (untreated) early-stage AD was compared before beginning ChEI (pre-ChEI) and after 3 months of therapy (post-ChEI) […]

Dysken, Maurice W., Guarino, Peter D., Vertrees, Julia E., Asthana, Sanjay, Sano, Mary, Llorente, Maria, Pallaki, Muralidhar, Love, Susan, Schellenberg, Gerard D., McCarten, J. Riley, Malphurs, Julie, Prieto, Susana, Chen, Peijun, Loreck, David J., Carney, Sara, Trapp, George, Bakshi, Rajbir S., Mintzer, Jacobo E., Heidebrink, Judith L., Vidal-Cardona, Ana, Arroyo, Lillian M., Cruz, Angel R., Kowall, Neil W., Chopra, Mohit P., Craft, Suzanne, Thielke, Stephen, Turvey, Carolyn L., Woodman, Catherine, Monnell, Kimberly A., Gordon, Kimberly, Tomaska, Julie, Vatassery, Govind

Background: Alzheimer’s disease (AD) has been associated with both oxidative stress and excessive glutamate activity. A clinical trial was designed to compare the effectiveness of (i) alpha-tocopherol, a vitamin E antioxidant; (ii) memantine (Namenda), an N-methyl-D-aspartate antagonist; (iii) their combination; and (iv) placebo in delaying clinical progression in AD.; Methods: The Veterans Affairs Cooperative Studies […]

Dysken, Maurice W., Sano, Mary, Asthana, Sanjay, Vertrees, Julia E., Pallaki, Muralidhar, Llorente, Maria, Love, Susan, Schellenberg, Gerard D., McCarten, J. Riley, Malphurs, Julie, Prieto, Susana, Chen, Peijun, Loreck, David J., Trapp, George, Bakshi, Rajbir S., Mintzer, Jacobo E., Heidebrink, Judith L., Vidal-Cardona, Ana, Arroyo, Lillian M., Cruz, Angel R., Zachariah, Sally, Kowall, Neil W., Chopra, Mohit P., Craft, Suzanne, Thielke, Stephen, Turvey, Carolyn L., Woodman, Catherine, Monnell, Kimberly A., Gordon, Kimberly, Tomaska, Julie, Segal, Yoav, Peduzzi, Peter N., Guarino, Peter D.

Importance: Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD.; Objective: To determine if vitamin E (alpha tocopherol), memantine, or both slow progression of mild to moderate AD in patients taking an acetylcholinesterase inhibitor.; Design, Setting, and Participants: […]

Albani, Diego, Martinelli Boneschi, Filippo, Biella, Gloria, Giacalone, Giacomo, Lupoli, Sara, Clerici, Francesca, Benussi, Luisa, Ghidoni, Roberta, Galimberti, Daniela, Squitti, Rosanna, Mariani, Stefania, Confaloni, Annamaria, Bruno, Giuseppe, Mariani, Claudio, Scarpini, Elio, Binetti, Giuliano, Magnani, Giuseppe, Franceschi, Massimo, Forloni, Gianluigi

Alzheimer’s disease (AD) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable, probably based on patients’ genetic background in donepezil metabolizing enzymes, including cytochrome 2D6 (CYP2D6). We evaluated the association between clinical response to donepezil and a common variant (rs1080985) of CYP2D6, previously reported to be associated with […]